Skip to main content

Table 1 Baseline and demographic characteristics (treated set)

From: Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

 

Total

(n = 149)

Age, yearsa

49.3 ± 13.3

Gender, n (%)

 

  Male

67 (45.0)

  Female

82 (55.0)

Body mass index, kg/m2 a

26.9 ± 4.3

Smoking status, n (%)

 

  Current smoker

0

  Ex-smoker

29 (19.5)

  Never smoked

120 (80.5)

Smoking history, pack-yearsa

5.6 ± 2.5

Duration of asthma, yearsa

23.8 ± 13.4

FEV1a

 

  % of predicted value pre-bronchodilation at screeningb

71.3 ± 7.1

  % of predicted value post-bronchodilation at screeningb

87.4 ± 10.2

  Reversibility, Lb

0.500 ± 0.239

  % reversibilityb

22.8 ± 10.2

  Pre-dose at study baseline, Lc

2.306 ± 0.689

FVC, pre-dose at baselinec, La

3.639 ± 0.978

FEV1/FVC ratio at baselinec, %a

63.7 ± 10.1

ICS dose of stable maintenance treatment, μga,d

659.2 ± 249.4

  1. aValues are mean ± standard deviation; bVisit 1; cMeasured 10 minutes prior to inhalation of study medication at Visit 2 (at randomisation); dBudesonide equipotent dose. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids.